FI3837256T3 - Ureayhdisteitä ja koostumuksia smarca2/brm-atpaasiestäjinä - Google Patents
Ureayhdisteitä ja koostumuksia smarca2/brm-atpaasiestäjinä Download PDFInfo
- Publication number
- FI3837256T3 FI3837256T3 FIEP19779145.2T FI19779145T FI3837256T3 FI 3837256 T3 FI3837256 T3 FI 3837256T3 FI 19779145 T FI19779145 T FI 19779145T FI 3837256 T3 FI3837256 T3 FI 3837256T3
- Authority
- FI
- Finland
- Prior art keywords
- carcinoma
- hydrogen
- pharmaceutically acceptable
- cell
- acceptable salt
- Prior art date
Links
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
- 239000001257 hydrogen Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 4
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 230000002381 testicular Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 208000006938 Schwannomatosis Diseases 0.000 claims 1
- 208000036822 Small cell carcinoma of the ovary Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 230000001120 cytoprotective effect Effects 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 201000005619 esophageal carcinoma Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000000121 hypercalcemic effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000004396 mastitis Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims 1
- 201000009494 neurilemmomatosis Diseases 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000011932 ovarian sarcoma Diseases 0.000 claims 1
- 201000005292 ovarian small cell carcinoma Diseases 0.000 claims 1
- 229940124641 pain reliever Drugs 0.000 claims 1
- -1 pain relievers Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765138P | 2018-08-17 | 2018-08-17 | |
| PCT/IB2019/056847 WO2020035779A1 (en) | 2018-08-17 | 2019-08-12 | Urea compounds and compositions as smarca2/brm atpase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3837256T3 true FI3837256T3 (fi) | 2023-05-15 |
Family
ID=68072895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19779145.2T FI3837256T3 (fi) | 2018-08-17 | 2019-08-12 | Ureayhdisteitä ja koostumuksia smarca2/brm-atpaasiestäjinä |
Country Status (21)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| CN112585136B (zh) | 2018-08-17 | 2024-06-25 | 诺华股份有限公司 | 作为smarca2/brm atp酶抑制剂的脲化合物和组合物 |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155262A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| EP4734993A2 (en) * | 2023-06-30 | 2026-05-06 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing drug-resistant cancer cells |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| US2871243A (en) * | 1956-10-26 | 1959-01-27 | May & Baker Ltd | 5-amino-3-methyl-isothiazole and process |
| AUPP003197A0 (en) | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| JP2002532415A (ja) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Mek阻害剤による関節炎の治療 |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| US7304066B2 (en) | 2001-05-24 | 2007-12-04 | Bjoerkling Fredrik | Pyridyl cyanoguanidine compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CA2478065C (en) | 2002-03-08 | 2013-01-08 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| JP2006521345A (ja) | 2003-03-28 | 2006-09-21 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ニコチン性アセチルコリン受容体の正のアロステリック調節剤 |
| MX2008002114A (es) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| CN103463084A (zh) | 2008-03-14 | 2013-12-25 | 大塚制药株式会社 | 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的肺气肿的药物中的应用 |
| CN103880737A (zh) * | 2014-02-27 | 2014-06-25 | 浙江泰达作物科技有限公司 | 1-(2-氯-4-吡啶基)-3-苯基脲的制备方法 |
| DK3169671T3 (da) | 2014-07-17 | 2019-09-23 | Sunshine Lake Pharma Co Ltd | 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| CN105481723B (zh) | 2015-04-29 | 2017-08-25 | 中国农业大学 | 一种非均相催化的烷基/苄基/芳基脲类化合物的制备方法 |
| WO2018187414A1 (en) | 2017-04-05 | 2018-10-11 | The Regents Of The University Of California | Inhibitors of mtor-rictor interactions |
| CN112585136B (zh) * | 2018-08-17 | 2024-06-25 | 诺华股份有限公司 | 作为smarca2/brm atp酶抑制剂的脲化合物和组合物 |
| WO2020126968A2 (en) | 2018-12-20 | 2020-06-25 | Bayer Aktiengesellschaft | Urea derivatives |
-
2019
- 2019-08-12 CN CN201980054231.1A patent/CN112585136B/zh not_active Expired - Fee Related
- 2019-08-12 CA CA3107097A patent/CA3107097A1/en active Pending
- 2019-08-12 HU HUE19779145A patent/HUE061963T2/hu unknown
- 2019-08-12 EP EP23160099.0A patent/EP4219488A1/en not_active Withdrawn
- 2019-08-12 DK DK19779145.2T patent/DK3837256T3/da active
- 2019-08-12 SI SI201930542T patent/SI3837256T1/sl unknown
- 2019-08-12 KR KR1020217007586A patent/KR20210047313A/ko active Pending
- 2019-08-12 EP EP19779145.2A patent/EP3837256B1/en active Active
- 2019-08-12 CN CN202410736812.6A patent/CN118666832A/zh active Pending
- 2019-08-12 MX MX2021001804A patent/MX2021001804A/es unknown
- 2019-08-12 PL PL19779145.2T patent/PL3837256T3/pl unknown
- 2019-08-12 LT LTEPPCT/IB2019/056847T patent/LT3837256T/lt unknown
- 2019-08-12 FI FIEP19779145.2T patent/FI3837256T3/fi active
- 2019-08-12 AU AU2019322325A patent/AU2019322325B2/en not_active Ceased
- 2019-08-12 RS RS20230377A patent/RS64238B1/sr unknown
- 2019-08-12 WO PCT/IB2019/056847 patent/WO2020035779A1/en not_active Ceased
- 2019-08-12 JP JP2021507613A patent/JP7328323B2/ja active Active
- 2019-08-12 US US17/268,512 patent/US11958846B2/en active Active
- 2019-08-12 BR BR112021002632-0A patent/BR112021002632A2/pt unknown
- 2019-08-12 PT PT197791452T patent/PT3837256T/pt unknown
- 2019-08-12 ES ES19779145T patent/ES2946060T3/es active Active
- 2019-08-12 HR HRP20230477TT patent/HRP20230477T1/hr unknown
-
2023
- 2023-06-02 CY CY20231100266T patent/CY1126039T1/el unknown
-
2024
- 2024-03-12 US US18/602,126 patent/US12358906B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240270738A1 (en) | 2024-08-15 |
| PL3837256T3 (pl) | 2023-07-10 |
| CN118666832A (zh) | 2024-09-20 |
| JP7328323B2 (ja) | 2023-08-16 |
| US20210323956A1 (en) | 2021-10-21 |
| AU2019322325B2 (en) | 2022-01-20 |
| EP3837256A1 (en) | 2021-06-23 |
| JP2021534147A (ja) | 2021-12-09 |
| HRP20230477T1 (hr) | 2023-07-21 |
| RS64238B1 (sr) | 2023-06-30 |
| SI3837256T1 (sl) | 2023-07-31 |
| AU2019322325A1 (en) | 2021-02-18 |
| CN112585136A (zh) | 2021-03-30 |
| CN112585136B (zh) | 2024-06-25 |
| LT3837256T (lt) | 2023-06-12 |
| EP4219488A1 (en) | 2023-08-02 |
| DK3837256T3 (da) | 2023-05-30 |
| ES2946060T3 (es) | 2023-07-12 |
| HUE061963T2 (hu) | 2023-09-28 |
| WO2020035779A1 (en) | 2020-02-20 |
| BR112021002632A2 (pt) | 2021-05-11 |
| US11958846B2 (en) | 2024-04-16 |
| KR20210047313A (ko) | 2021-04-29 |
| PT3837256T (pt) | 2023-05-23 |
| EP3837256B1 (en) | 2023-03-08 |
| CA3107097A1 (en) | 2020-02-20 |
| CY1126039T1 (el) | 2023-11-15 |
| MX2021001804A (es) | 2021-04-19 |
| US12358906B2 (en) | 2025-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230477T1 (hr) | Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze | |
| CA2380904C (en) | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer | |
| HRP20230400T1 (hr) | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| MX2022013657A (es) | Quimioterápicos de éter macrocíclico heteroaromático. | |
| FI3500299T3 (fi) | Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa | |
| IL299099B1 (en) | Combinations of cancer treatments | |
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| JP2021534147A5 (cg-RX-API-DMAC7.html) | ||
| MY158494A (en) | Pharmaceutically active compounds as axl inhibitors | |
| ME02460B (me) | Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor | |
| CA2649549A1 (en) | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds | |
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
| AU2015217450A8 (en) | Pyrazolone compounds and uses thereof | |
| TNSN07294A1 (en) | Treatment of metastasized tumors | |
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| EA027986B9 (ru) | Соединения триазолона и их применение | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| WO2013095286A3 (en) | Synergistic combination comprising avermectins and a nsaid for tumor inhibition | |
| RU2014112320A (ru) | Ингибитор pi3k, предназначенный для применения для лечения рака кости или для предупреждения метастатической диссеминации первичных раковых клеток в кость | |
| US20260041676A1 (en) | Combination Therapy | |
| EP3324974B1 (en) | Compounds, compositions, methods for treating diseases, and methods for preparing compounds | |
| RU2012140020A (ru) | Гетероциклические соединения и их применение в качестве противораковых средств | |
| RU2021106362A (ru) | Соединения на основе мочевины и композиции на их основе в качестве ингибиторов атфазы smarca2/brm | |
| Yoshizawa et al. | Anti-Tumour Efficacy Study Of The Bruton's Tyrosine Kinase (Btk) Inhibitor, ONO-4059, In Combination With The Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab (GA101) Demonstrates Superior In Vivo Efficacy Compared To ONO-4059 In Combination With Rituximab |